It was found that in a wild-type mouse model of colitis-associated cancer, blockade of the TLR4/MyD88 signaling pathway using a MyD88 inhibitor reduces the proliferative capacity and promotes apoptosis of colonic epithelial cells, decreases serum TNF-α and IL-6 secretion, alleviates the inflammatory response of the intestinal tract, and inhibits tumor formation [21]. Here, MYD88 is linked to colitis.